Could stem cell secretions tame tough Crohn's? new trial aims to find out

NCT ID NCT07625293

Not yet recruiting Disease control Sponsor: Direct Biologics, LLC Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests a new treatment called DB-3Q for people with Crohn's disease that hasn't improved with standard therapies. DB-3Q is made from stem cells and may help reduce inflammation in the gut. The trial will enroll 36 adults and focus on safety and how well the treatment works, using a scoring system from colonoscopies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DB-3Q (a product made from stem cells that may help reduce inflammation)
What this could lead to: If successful, this could point toward a new treatment option for people with Crohn's disease that hasn't responded to other therapies.
What could go wrong: This is an early Phase 2a study with only 36 participants, so results may not apply to everyone. The treatment is still experimental and its safety and effectiveness are not yet proven.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CROHN DISEASE (CD) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Crohn disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CROHN DISEASE (CD)

Contacts and locations

Locations

Washington University, St. Louis

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.